iBio (IBIO) Stock Price, News & Analysis

Company Overview

iBio, Inc. is a clinical-stage biotechnology company specializing in plant-based expression systems to develop and manufacture therapeutic proteins and vaccines. The company’s proprietary FastPharming™ technology harnesses a transient expression platform in plant cells, enabling rapid production of recombinant biologics. This approach is designed to offer an alternative to traditional mammalian or microbial cell culture systems, with potential benefits in speed, scalability and cost-effectiveness.

Through its iBio CDMO division, iBio provides contract development and manufacturing services to pharmaceutical and biotechnology clients. Offerings include process development, analytical method development, and cGMP manufacturing of clinical- and commercial-scale biologics. The company’s integrated service model is intended to support candidates from early-stage development through commercial launch, encompassing activities such as gene construct optimization, upstream and downstream processing, and quality control testing.

Founded in 2000 as IBIO, Inc., the company has evolved its business by acquiring Greenovation Biotech GmbH in 2016, expanding its capabilities in Europe. In 2020, iBio opened its cGMP-compliant biomanufacturing facility in Bryan, Texas, near Texas A&M University, marking a significant milestone in its capacity to produce clinical-grade materials. The company’s headquarters are located in New York, reflecting its origins and ongoing strategic focus on U.S. innovation hubs.

iBio serves a global client base, with operations and collaborations spanning the United States and Europe. By leveraging its plant-based system, the company aims to address the growing demand for flexible biomanufacturing solutions and to accelerate the development of vaccines and therapeutic proteins for emerging health threats and chronic diseases.

Key Stats

• Today's Range: $0.82 to $0.87
• 50-Day Range: $0.57 to $0.86
• 52-Week Range: $0.56 to $6.89
• Volume: 347,220 shs
• Average Volume: 1.50 million shs
• Market Capitalization: $2.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

iBio Stock Analysis - MarketRank™

iBio scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for iBio.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

iBio has a P/B Ratio of 0.05. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.09% of the float of iBio has been sold short.

Short Interest Ratio / Days to Cover

iBio has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in iBio has recently increased by 104.12%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

iBio does not currently pay a dividend.

Dividend Growth

iBio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.09% of the float of iBio has been sold short.

Short Interest Ratio / Days to Cover

iBio has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in iBio has recently increased by 104.12%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Sentiment

iBio has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.

Search Interest

Only 1 people have searched for IBIO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, iBio insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.12% of the stock of iBio is held by insiders.

Percentage Held by Institutions

Only 7.90% of the stock of iBio is held by institutions.

IBIO Stock Analysis - Frequently Asked Questions

How have IBIO shares performed this year?

iBio's stock was trading at $2.42 at the start of the year. Since then, IBIO shares have decreased by 65.6% and is now trading at $0.8328.

How do I buy shares of iBio?

Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of iBio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that iBio investors own include Mesoblast (MESO), Mobileye Global (MBLY), KULR Technology Group (KULR), IonQ (IONQ), Guardforce AI (GFAI), Fastly (FSLY) and Exscientia (EXAI).

Company Calendar

• Today: 9/10/2025
• Next Earnings (Estimated): 9/19/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:IBIO
• CIK: 1420720
• Web: www.ibioinc.com
• Phone: 302-355-0650
• Fax: 302-356-1173
• Employees: 100
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$65.01 million
• Net Margins: N/A
• Pretax Margin: -41,546.00%
• Return on Equity: -150.59%
• Return on Assets: -52.83%

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 0.91
• Quick Ratio: 0.91

Sales & Book Value

• Annual Sales: $2.38 million
• Price / Sales: 1.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $15.15 per share
• Price / Book: 0.05

Miscellaneous

• Outstanding Shares: 3,480,000
• Free Float: 3,445,000
• Market Cap: $2.90 million
• Optionable: N/A
• Beta: -3.77